Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looks like Genmab beefing up legal teams in USA .
Their KYO time line seems to be working
We also know close relationship with Scancell noted LD was tight lipped
Good posts this morning from
Chill time over on the other side
From jobs
https://www.goinhouse.com
After it announced this week
Director, Legal Counsel (US Market Operations)
* Genmab
* Princeton, NJ
Apr 23
* Director, Patent Attorney
* Genmab
* Princeton, NJ
Apr 15
Recent Genmab news
May 2, 2024 at 5:02 PM CEST
Genmab Announces Financial Results for the First Quarter of 2024
Download
Apr 30, 2024 at 12:40 AM CEST
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Apr 29, 2024 at 10:24 AM CEST
Transactions in Connection with Share Buy-back Program Genmab
Download
Download
Thanks CW, Should help Scancell receive proper notice. IMO
Interesting find CW/chilltime.
I found the job link:
https://genmab.wd3.myworkdayjobs.com/en-US/Genmab_Careers_Site/job/Director--Patent-Attorney_R10059
I found these job requirements interesting, though not fully understanding the implications?
"... Your job will include preparing IP strategies, drafting and prosecuting patent applications, reviewing documents prior to publication, ***evaluating third party patent rights***"
"Survey third party patent positions, file relevant actions, and solicit legal opinions against third party patent rights."
Also this is the other role
Director, Legal Counsel (US Market Operations)
Your job will include reviewing, drafting and negotiating agreements for the Market Operations Team, be part of the cross functional group reviewing commercial and scientific materials, provide relevant legal training to sales representatives and others, and provide legal support regarding various types of contracts and engagements
*
* Responsible for legal review of scientific and commercial/marketing material for use in the US Market in close cooperation with Genmab colleagues but also with Genmab collaboration partners.
* Support Marketing and Sales with negotiation, drafting and/or review of commercial agreements
Support Medical Affairs with negotiation, drafting and/or review of agreements (e.g., Advisory Boards) and provide legal review of scientific materials
* Support Market Access by providing legal advice relating to patient support programs, and drafting/ reviewing of applicable agreements (e.g., with service providers for various patient support programs), and providing legal advice relating to arrangements and agreements with various entities in the health care delivery system (including payers, specialty distributors/distributors, GPOs and health care providers and institutions)
With respect, I don’t understand the relevance to Scancell of these jobs at Genmab. Of course I understand they are evaluating a Scancell product but the fact they are recruiting for Director roles in their wider organisation, carries no relevance whatsoever to that in my opinion.
We only have one commercial deal and it’s with Genmab on the Glymab platform. Ld has said someone might want exclusivity! We know there is also interest in them taking another Glymab as they are “happy “ with the one that they have
Chelsea I would like to see some of your research on why it’s not relevant as a counter argument?
Cleaner - you obviously have no idea how many companies Genmab are working with. To think that they are recruiting for senior postions in their organisation with direct relevance to Scancell is ludicrous. It is just general recruitment, the same as any other large pharma recruit all the time - should we post all their vacancies too? However I’ll give you 10 out of 10 for imagination.
I'm with C11. It's a tenuous connection at best.
Genmab have such a big pipeline and, if they trial products discovered by other companies, they need to do due diligence on the science but also due diligence on the business and patent aspects of any deal.
100%
CW as always keeps on posting and creating chats on subjects with no direct connection. What a waste of time and space.
…and all is under the research banner. Between him and inanaco they contribute 99% of the white noise.
And what do you have to offer Lofas? Confusion, contradiction and FUD perhaps? For someone who has written this share off you seem awfully interested.
I'm pretty sure CW is not a "him" by the way. But there you go go again, shooting your mouth off without a clue.
Don’t ofer pointers pointing to nowhere. No need to say anything if there is nothing to say …. Policy adapted by Scancell .